The safety and immunogenicity of vaccines administered to pregnant women living with HIV: a systematic review and meta-analysis

Nakabembe, Eve; Cooper, Jo; Amaral, Kyle; Tusubira, Valerie; Hsia, Yingfen; Abu-Raya, Bahaa; Sekikubo, Musa; Nakimuli, Annettee; Sadarangani, Manish; Le Doare, Kirsty

doi:10.1016/j.eclinm.2024.102448

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mRNA-1893 vaccine, tested in the USA and Puerto Rico, exhibited mostly mild to moderate adverse reactions at higher doses, yet induced robust and persistent Zika-virus-specific nAb responses in all participants by day 57, irrespective of their flavivirus serostatus. These favorable results, supporting the development of mRNA-1893 against Zika virus, highlight its tolerability and ability to generate strong nAb responses [ 72 ].…”

Section: Recent Advances In Mrna Vaccinesmentioning

confidence: 94%

Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses

Kutikuppala,

Kourampi,

Kanagala

et al. 2024

Medical Sciences

View full text Add to dashboard Cite

mRNA vaccines have emerged as an optimistic technological platform for vaccine innovation in this new scientific era. mRNA vaccines have dramatically altered the domain of vaccinology by offering a versatile and rapid approach to combating infectious diseases and virus-induced cancers. Clinical trials have demonstrated efficacy rates of 94–95% in preventing COVID-19, and mRNA vaccines have been increasingly recognized as a powerful vaccine platform. Although mRNA vaccines have played an essential role in the COVID-19 pandemic, they still have several limitations; their instability and degradation affect their storage, delivery, and over-all efficiency. mRNA is typically enclosed in a transport mechanism to facilitate its entry into the target cell because it is an unstable and negatively charged molecule. For instance, mRNA that is given using lipid-nanoparticle-based vaccine delivery systems (LNPs) solely enters cells through endocytosis, establishing an endosome without damaging the cell membrane. The COVID-19 pandemic has accelerated the development of mRNA vaccine platforms used to treat and prevent several infectious diseases. This technology has the potential to change the future course of the disease by providing a safe and effective way to combat infectious diseases and cancer. A single-stranded genetic sequence found in mRNA vaccines instructs host cells to produce proteins inside ribosomes to elicit immunological responses and prepare the immune system to fight infections or cancer cells. The potential applications of mRNA vaccine technology are vast and can lead to the development of a preferred vaccine pattern. As a result, a new generation of vaccinations has gradually gained popularity and access to the general population. To adapt the design of an antigen, and even combine sequences from different variations in response to new changes in the viral genome, mRNA vaccines may be used. Current mRNA vaccines provide adequate safety and protection, but the duration of that protection can only be determined if further clinical research is conducted.

show abstract

Section: Recent Advances In Mrna Vaccinesmentioning

confidence: 94%